Incannex Healthcare Share Price and Company Fundamentals
Last traded: Today at 6:10 AM
Incannex Healthcare Limited engages in the research, development, and sale of medicinal cannabinoid products in Australia. It offers pharmaceutical grade cannabinoid products under the Incannex brand name. The company's therapeutic products in clinical trials include IHL-42X for obstructive sleep apnea; IHL-216A for traumatic brain injury; IHL-675A for sepsis associated acute respiratory distress syndrome; and IHL-493C for temporomandibular joint dysfunction. It has partnership with The Alfred Hospital and Novotech on IHL-42X clinical program for obstructive sleep apnea. Incannex Healthcare Limited has a partnership with Monash Trauma Group at the Department of Neuroscience, Monash University to conduct an in vivo study on the protective effect of IHL-216A in sports concussion. The company was formerly known as Impression Healthcare Limited and changed its name to Incannex Healthcare Limited in June 2020. Incannex Healthcare Limited is based in Melbourne, Australia.
|Industry / Sector||Drug Manufacturers—Specialty & Generic / Healthcare|
|Mailing address||Rialto South Tower Level 39 525 Collins Street Melbourne VIC 3000 Australia|
|Phone / Fax||61 4 2570 3805 /|
|Share registry||AUTOMIC REGISTRY SERVICES|
Incannex Healthcare does not pay dividends.
As of May 2021, following are the company executives and directors listed on Incannex Healthcare.
|Mr. Joel Bradley Latham||MD, CEO & Exec. Director||336.67k|
|Dr. Sud Agarwal B.Sc.||Chairman of Medical Advisory Board, Chief Medical Officer & Non-Exec. Director||130.65k|
|Mr. John Michailidis B.Sc., EMBA, M.A.I.C.D.||Chief Exec. Officer of IncannexTM|
|Mr. Glenn Fowles BBS||Company Sec.|
Profitability and management effectiveness
Return on assets
Return on equity
Profitability ratios are a class of financial metrics that are used to assess a business's ability to generate earnings relative to its revenue, operating costs, balance sheet assets, and shareholders' equity over time, using data from a specific point in time.
The return on equity signifies how well the management is running the company in terms of capital management. The ideal return on equity is greater than 10%. The return on equity is calculated as net income divided by total share holders equity.
Valuation and Trading Info
The market capitalization of Incannex Healthcare is 285.9M and its enterprise value is 310.56M. The enterprise value to revenue ratio of IHL is 174.55.
The IHL's stocks Beta value is 1.98 making it 98% more volatile compared to ASX market index. Technology stocks and small caps tend to have higher betas than the market benchmark. This indicates that adding the stock to a portfolio will increase the portfolio’s risk, but also increase its expected return. On the other hand utility stocks often have low betas because they tend to move more slowly than market averages.
Companies similar to Incannex Healthcare (IHL)
Incannex Healthcare (ASX:IHL) Frequently Asked Questions
1. What is Incannex Healthcare's Stock Symbol?
Incannex Healthcare trades on ASX under the ticker symbol "IHL".
2. What is Incannex Healthcare's stock price today?
One share of IHL stock can currently be purchased for approximately $0.27.
3. How can I contact Incannex Healthcare?
Incannex Healthcare's mailing address is Rialto South Tower Level 39 525 Collins Street Melbourne VIC 3000 Australia. The company can be reached via phone at 61 4 2570 3805.
4. What is Incannex Healthcare's official website?
The official website of Incannex Healthcare is http://www.incannex.com.au.
5. Which share registry manages Incannex Healthcare's stock?
Incannex Healthcare's stock is managed by AUTOMIC REGISTRY SERVICES.